Trial Profile
A phase III study of tarenflurbil spray for the treatment of skin diseases.
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 22 Jan 2016
Price :
$35
*
At a glance
- Drugs Tarenflurbil (Primary)
- Indications Skin disorders
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- 22 Jan 2016 New trial record
- 12 Dec 2008 According to a MIKA Pharma GmbH media release, phase III proof-of-concept trial will be finance by GALEN pharma.